Literature DB >> 22398963

Outcomes of acute phase cognitive therapy in outpatients with anxious versus nonanxious depression.

Jasper A J Smits1, Abu Minhajuddin, Michael E Thase, Robin B Jarrett.   

Abstract

OBJECTIVE: Compared to nonanxious depressed patients, anxious depressed patients respond less to pharmacotherapy, prompting consideration of alternate treatments. Based on the transdiagnostic principles of cognitive therapy (CT), we predicted that anxious depressed patients would respond as well to CT as nonanxious depressed patients.
METHOD: Adults (n = 523) with recurrent major depressive disorder received 12-14 weeks of CT as part of the Continuation Phase Cognitive Therapy Relapse Prevention Trial. Anxious depressed patients (n = 264; 50.4%) were compared to nonanxious depressed patients (n = 259; 49.6%) on demographic variables, initial severity, attrition, and rates and patterns of response and remission.
RESULTS: Anxious depressed patients presented with greater illness severity and had significantly lower response (55.3 vs. 68.3%) and remission rates (26.9 vs. 40.2%) based on clinician-administered measures. By contrast, smaller between-group differences for attrition, and for response (59.1 vs. 64.9%) and remission (41.7 vs. 48.7%) rates on self-report measures were not significant. Further, anxious depressed patients had greater speed of improvement on self-reported anxiety symptom severity and clinician-rated depressive and anxiety symptom severity measures.
CONCLUSION: Consistent with prior reports, anxious depressed patients presented with greater severity and, following CT, had lower response and remission rates on clinician-administered scales. However, anxious depressed patients improved more rapidly and response and remission rates on self-report measures were not significantly different from nonanxious depressed patients. Our findings suggest that anxious depressed patients may simply need additional time or more CT sessions to reach outcomes fully comparable to those of less anxious patients.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2012        PMID: 22398963      PMCID: PMC3362240          DOI: 10.1159/000334909

Source DB:  PubMed          Journal:  Psychother Psychosom        ISSN: 0033-3190            Impact factor:   17.659


  26 in total

1.  Are treatment preferences relevant in response to serotonergic antidepressants and cognitive-behavioral therapy in depressed primary care patients? Results from a randomized controlled trial including a patients' choice arm.

Authors:  Roland Mergl; Verena Henkel; Antje-Kathrin Allgaier; Dietmar Kramer; Martin Hautzinger; Ralf Kohnen; James Coyne; Ulrich Hegerl
Journal:  Psychother Psychosom       Date:  2010-10-23       Impact factor: 17.659

2.  The Cognitive Therapy Scale: psychometric properties.

Authors:  T M Vallis; B F Shaw; K S Dobson
Journal:  J Consult Clin Psychol       Date:  1986-06

3.  A functional anlysis of depression.

Authors:  C B Ferster
Journal:  Am Psychol       Date:  1973-10

4.  Abnormal electroencephalographic sleep profiles in major depression: association with response to cognitive behavior therapy.

Authors:  M E Thase; A D Simons; C F Reynolds
Journal:  Arch Gen Psychiatry       Date:  1996-02

5.  Preventing recurrent depression using cognitive therapy with and without a continuation phase: a randomized clinical trial.

Authors:  R B Jarrett; D Kraft; J Doyle; B M Foster; G G Eaves; P C Silver
Journal:  Arch Gen Psychiatry       Date:  2001-04

6.  Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatment.

Authors:  M E Thase; A D Simons; J McGeary; J F Cahalane; C Hughes; T Harden; E Friedman
Journal:  Am J Psychiatry       Date:  1992-08       Impact factor: 18.112

7.  Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.

Authors:  Jonathan R T Davidson; Paolo Meoni; Vincent Haudiquet; Marc Cantillon; David Hackett
Journal:  Depress Anxiety       Date:  2002       Impact factor: 6.505

8.  Anxious and nonanxious depression.

Authors:  R T Joffe; R M Bagby; A Levitt
Journal:  Am J Psychiatry       Date:  1993-08       Impact factor: 18.112

9.  The Inventory for Depressive Symptomatology (IDS): preliminary findings.

Authors:  A J Rush; D E Giles; M A Schlesser; C L Fulton; J Weissenburger; C Burns
Journal:  Psychiatry Res       Date:  1986-05       Impact factor: 3.222

Review 10.  Defining anxious depression: going beyond comorbidity.

Authors:  Peter H Silverstone; Erica von Studnitz
Journal:  Can J Psychiatry       Date:  2003-11       Impact factor: 4.356

View more
  11 in total

1.  The Role of Dyadic Discord in Outcomes in Acute Phase Cognitive Therapy for Adults With Recurrent Major Depressive Disorder.

Authors:  Joseph M Trombello; Jeffrey R Vittengl; Wayne H Denton; Abu Minhajuddin; Michael E Thase; Robin B Jarrett
Journal:  Behav Ther       Date:  2018-12-06

2.  Preventing depressive relapse and recurrence in higher-risk cognitive therapy responders: a randomized trial of continuation phase cognitive therapy, fluoxetine, or matched pill placebo.

Authors:  Robin B Jarrett; Abu Minhajuddin; Howard Gershenfeld; Edward S Friedman; Michael E Thase
Journal:  JAMA Psychiatry       Date:  2013-11       Impact factor: 21.596

3.  Anxious depression as a clinically relevant subtype of pediatric major depressive disorder.

Authors:  Isabelle Häberling; Noemi Baumgartner; Sophie Emery; Paola Keller; Michael Strumberger; Kristin Nalani; Klaus Schmeck; Suzanne Erb; Silke Bachmann; Lars Wöckel; Ulrich Müller-Knapp; Brigitte Contin-Waldvogel; Bruno Rhiner; Susanne Walitza; Gregor Berger
Journal:  J Neural Transm (Vienna)       Date:  2019-08-27       Impact factor: 3.575

4.  Do comorbid social and other anxiety disorders predict outcomes during and after cognitive therapy for depression?

Authors:  Jeffrey R Vittengl; Lee Anna Clark; Jasper A J Smits; Michael E Thase; Robin B Jarrett
Journal:  J Affect Disord       Date:  2018-08-25       Impact factor: 4.839

5.  Neuromodulation Treatments of Pathological Anxiety in Anxiety Disorders, Stressor-Related Disorders, and Major Depressive Disorder: A Dimensional Systematic Review and Meta-Analysis.

Authors:  Gay Florian; Allison Singier; Bruno Aouizerate; Francesco Salvo; Thomas C M Bienvenu
Journal:  Front Psychiatry       Date:  2022-07-01       Impact factor: 5.435

6.  Treating co-occurring depression and anxiety: modeling the dynamics of psychopathology and psychotherapy using the time-varying effect model.

Authors:  Aidan G C Wright; Michael N Hallquist; Holly A Swartz; Ellen Frank; Jill M Cyranowski
Journal:  J Consult Clin Psychol       Date:  2013-09-16

7.  Identifying moderators of the adherence-outcome relation in cognitive therapy for depression.

Authors:  Katherine E Sasso; Daniel R Strunk; Justin D Braun; Robert J DeRubeis; Melissa A Brotman
Journal:  J Consult Clin Psychol       Date:  2015-07-27

8.  D-cycloserine augmentation of cognitive behavioral group therapy of social anxiety disorder: prognostic and prescriptive variables.

Authors:  Jasper A J Smits; Stefan G Hofmann; David Rosenfield; Lindsey B DeBoer; Paul T Costa; Naomi M Simon; Conall O'Cleirigh; Alicia E Meuret; Luana Marques; Michael W Otto; Mark H Pollack
Journal:  J Consult Clin Psychol       Date:  2013-08-12

Review 9.  Using patient self-reports to study heterogeneity of treatment effects in major depressive disorder.

Authors:  R C Kessler; H M van Loo; K J Wardenaar; R M Bossarte; L A Brenner; D D Ebert; P de Jonge; A A Nierenberg; A J Rosellini; N A Sampson; R A Schoevers; M A Wilcox; A M Zaslavsky
Journal:  Epidemiol Psychiatr Sci       Date:  2016-01-26       Impact factor: 6.892

10.  Predictors of Response to Web-Based Cognitive Behavioral Therapy With High-Intensity Face-to-Face Therapist Guidance for Depression: A Bayesian Analysis.

Authors:  Ragnhild Sørensen Høifødt; Matthias Mittner; Kjersti Lillevoll; Susanne Kvam Katla; Nils Kolstrup; Martin Eisemann; Oddgeir Friborg; Knut Waterloo
Journal:  J Med Internet Res       Date:  2015-09-02       Impact factor: 5.428

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.